Don’t miss out – Get your tickets early!
Join this FREE, 75-minute online webinar to gain access to insights and learn about groundbreaking treatments to chronic mental health conditions.
Robin Carhart-Harris (USA) will explore how psychedelic-assisted therapy works by:
· Addressing and explaining the pharmacology of classic psychedelics
· Detailing their effect on neuroplasticity
· Explaining the acute action of psychedelics on the human brain and how that maps to their phenomenology
· Covering a model of how psychedelic therapy is transdiagnostically effective
· Explaining findings from a psilocybin therapy vs escitalopram clinical trial
Date: Wednesday 15 March 2023
Time: 12:55pm for 1:00pm start – 2:15pm (incl Q&A) (AEDT)
The presentation WILL BEGIN AT 1:00pm.
Location: Online. A link will be emailed to you with the viewing details once you have registered.
Following the presentation there will be a Q & A panel with Dr Robin Carhart-Harris and Tania de Jong AM. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
Support these events:
Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.
More about Mind Medicine Australia and medicinal psychedelic-assisted therapy:
Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients.
Unlike current treatments such as anti-depressants, which only manage the illness and can have nasty side effects, psilocybin and MDMA assisted therapies have been scientifically proven to be a safe and effective cure for anxiety, depression, end-of-life stress, addictions and PTSD after just a short treatment program. These medicines are also currently being researched for dementia, eating disorders, OCD and a number of other conditions. Both medicines have been granted Breakthrough Therapy Status by the FDA in the USA to fast-track their approval. This designation is only given to medicines which may prove to be vastly superior to existing treatments.
At Mind Medicine Australia we are dedicated to helping the now global movement to spread this awareness and ensure these medicines are available via the medical system. Please watch and share our 2 minute animation to find out why psychedelic-assisted psychotherapy needs to be available to those who are suffering.
Prof Robin Carhart-Harris (UK)
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, he has run and overseen brain imaging studies involving LSD, psilocybin, MDMA and DMT, plus a clinical trial of psilocybin for treatment-resistant depression, and a current study comparing psilocybin with escitalopram for major depressive disorder. In 2019, he set-up the Centre for Psychedelic Research at Imperial and he also an honorary position with the University of Oxford. Two of his most influential works include the ‘Entropic Brain Hypothesis’ and ‘REBUS and the anarchic brain’.